ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,110 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentHorgenCDR-Life AG
CDR-Life AG Logo
Verified· 3 sources

CDR-Life AG

Summary

About the company

The company develops and commercializes new medicines, particularly T-cell activated cancer medicines, and provides services in the areas of research and development, clinical trials, pharmacology, toxicology and analytics.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Pharmaceutical Industry
✓ Offered10
Antibody-based T-cell engagers
Antibody-based T-cell engagers for oncology and autoimmune diseases, developed with the M-gager® platform for high tumor selectivity and targeted immune-cell control.
M-gager® platform
Proprietary antibody-fragment platform for developing selective T-cell engagers, with a modular binding architecture, good drug properties and scalable manufacturing.
Oncology programs
Tumor-selective T-cell engagers against solid tumors that are difficult to treat, including CDR404, CDR505, CDR609 and CDR813 for different cancer antigens.
Autoimmunity programs
Targeted therapeutics for autoimmune diseases that address specific immune-cell populations and aim to reset the immune system to a healthy state.
CDR404
Bivalent, bispecific M-gager® against MAGE-A4-positive solid tumors, currently in a Phase 1 study evaluating safety, tolerability and first efficacy.
CDR609
Antibody-based M-gager® against LGR5-expressing solid tumors, developed as a next-generation T-cell engager for selective recruitment of T-cells.
CDR505
Tumor-selective M-gager® against KK-LC-1 on HLA-A*01, designed for common cancers and a patient population that has not yet been addressed.
CDR813
Differentiated M-gager® against PRAME with high potency and specificity to treat cancer cells without targeting normal tissue.
CDR111
T-cell engager against two B-cell targets for effective B-cell depletion, with a potential curative approach in multiple autoimmune diseases.
Partnerships and R&D collaborations
Partnerships with pharmaceutical companies, academic partners and other stakeholders, including joint development and licensing of new targets via the M-gager® platform.
Press

Media

November 6, 2025Media
CDR-Life strikes CHF 456 million deal with Boehringer Ingelheim
venturelab.swiss
November 5, 2025Media
CDR-Life to receive up to CHF 456 million in license agreement with Boehringer Ingelheim
startupticker.ch
September 16, 2024Media
Positive clinical progress in the biotech scene
startupticker.ch
December 14, 2023Media
CDR-Life advances into the clinical phase
startupticker.ch
May 11, 2021Media
CDR-Life moves towards clinical trials
startupticker.ch
Comparisons

CDR-Life AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank CDR-Life AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of CDR-Life AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Tödistrasse 46
8810 Horgen

At a glance

Legal form
Corporation
UID
CHE-255.051.249
Founded
2017 · 9 years
Last commercial register change
July 8, 2026
Employees
51 to 100

Knowledge

No knowledge articles yet

Once CDR-Life AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

NS
NILT Switzerland GmbH
Horgen
NT
Numab Therapeutics AG
Horgen
SB
Seito Biologics AG
Küsnacht Zh
SA
Sensoryx AG
Zurich
PA
Philochem AG
Otelfingen
CA
CHoNova AG
Oberhasli
MA
Mabylon AG
Schlieren
FF
Forschungsstiftung für Informationstechnologie und Gesellschaft
Zurich